Markets:

Overview

News

Currencies

International

Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

41.03 UNCHANGED

Last Price Updated: 4:00 PM EDT, May 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

July 17, 2023

It's time to start off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday!

Via InvestorPlace

The Latest Analyst Ratings for Apellis Pharmaceuticals ↗

June 13, 2023

Via Benzinga

The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗

June 02, 2023

Big Pharma is facing a patent cliff that could siphon off billions in revenue.

Via Investor's Business Daily

Apellis Pharma Flunks On Primary, Secondary Endpoints In Amyotrophic Lateral Sclerosis Study ↗

May 25, 2023

Via Benzinga

Needham Maintains Buy Rating for Apellis Pharmaceuticals: Here's What You Need To Know ↗

May 05, 2023

Via Benzinga

Top-Notch Biotech Apellis Soars After New Drug Obliterates Sales Views ↗

May 05, 2023

The company easily beat sales calls on the back of Syfovre, a geography atrophy drug.

Via Investor's Business Daily

The Latest Analyst Ratings for Apellis Pharmaceuticals ↗

May 05, 2023

Via Benzinga

Why Shares of Annexon Are Plummeting Thursday ↗

May 25, 2023

Mixed trial results on a geographic atrophy eye drug led investors to sell the biotech stock.

Via The Motley Fool

Why These 3 Nasdaq Stocks Buckled Today ↗

May 16, 2023

The FTC's decision to sue to block a high-profile merger is weighing on biotech valuations today.

Via The Motley Fool

Apellis Pharma's Newly Approved Drug Exceeds Sales Projections, Bullish Analyst Raises Expectations ↗

May 05, 2023

Apellis Pharmaceuticals Inc (NASDAQ: APLS) reported Q1 revenues of $44.8 million, surpassing the consensus of $26.10 million and

Via Benzinga

Apellis Pharmaceuticals: Q1 Earnings Insights ↗

May 04, 2023

Via Benzinga

Earnings Preview: Apellis Pharmaceuticals ↗

May 03, 2023

Via Benzinga

Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today ↗

May 01, 2023

These three biotech stocks were on the volatile side today.

Via The Motley Fool

Wedbush Maintains Neutral Rating for Apellis Pharmaceuticals: Here's What You Need To Know ↗

April 17, 2023

Via Benzinga

9 Analysts Have This to Say About Apellis Pharmaceuticals ↗

April 14, 2023

Via Benzinga

Why Apellis Pharmaceuticals Stock Is Soaring Today ↗

April 03, 2023

Rare disease-focused Apellis Pharmaceuticals Inc (NASDAQ: APLS) is reportedly drawing takeover interest from large drugmakers.

Via Benzinga

2 Best Growth Stocks to Buy in April ↗

April 03, 2023

Takeover interest is spurring these two biotech stocks higher.

Via The Motley Fool

Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma ↗

May 01, 2023

The company is working on a treatment for the eye disease known as geographic atrophy.

Via Investor's Business Daily

Top 5 Health Care Stocks That Could Sink Your Portfolio This Quarter ↗

April 27, 2023

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

April 26, 2023

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

April 19, 2023

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

April 12, 2023

Via Benzinga

Apellis Pharmaceuticals's Return On Capital Employed Insights ↗

February 22, 2023

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

April 03, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

April 03, 2023

Via Benzinga

Apellis Pharmaceuticals, VirTra And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗

April 03, 2023

U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

Wall Street Upgraded This Stock's Price Target After a New Approval: Is It a Buy? ↗

February 27, 2023

The company's lead therapy was just approved for another indication.

Via The Motley Fool

Why Apellis Pharmaceuticals Stock Surged This Week ↗

February 24, 2023

A highly eventful five days for the company saw bulls pile into its shares.

Via The Motley Fool

Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

February 21, 2023

Gainers Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023.

Via Benzinga

Apellis Surges To Four-Month High — Sending Rival Iveric Tumbling — On A First-Ever Approval ↗

February 21, 2023

Apellis is soon to launch its newest drug, Syfovre, for geographic atrophy patients.

Via Investor's Business Daily

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.